TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase 1b trial studies the side effects and best dose of TAS-102 when given together
with radiation therapy in treating patients with stage II-III rectal cancer that has not been
treated and can be removed by surgery (resectable). Drugs used in chemotherapy, such as
TAS-102, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy
uses high energy x-rays to kill tumor cells and shrink tumors. This study is being done to
find out the safest dose of TAS-102 that can be used with radiation treatment for rectal
cancer.
Phase:
Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
National Cancer Institute (NCI) Oregon Health and Science University Taiho Oncology Taiho Pharmaceutical Co., Ltd.